Johnson & Johnson consensus stays steady, shares supported by dividend profile

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-25, 19:13.

Johnson & Johnson (US4781601046) starts the week with a stable analyst picture and a robust dividend profile, while the shares continue to trade on the NYSE close to their 52-week range highs. According to market data, the stock last changed hands around 241 dollars, roughly 4 percent below the 52-week high near 252 dollars on the New York Stock Exchange.

What analysts are saying now

On MarketBeat, Johnson & Johnson is covered by more than a dozen research houses, with the aggregated rating sitting in the "Moderate Buy" zone and an average 12-month price target around 183 dollars per share as of the latest update. The same overview shows that the highest published target price reaches into the low 200s, while the lowest sits clearly below the current NYSE quote, underscoring a spread of opinions among brokers. MarketBeat’s Johnson & Johnson consensus page

Fidelity data put the Johnson & Johnson dividend yield at roughly 2.3 percent based on a share price near 241 dollars and the current annualized payout. The same source lists earnings per share around 12 dollars, which implies a price-earnings ratio in the high 20s at recent trading levels, positioning the company toward the upper end of the large-cap pharma peer group on this metric. Fidelity factsheet on Johnson & Johnson

Where the shares trade on NYSE and in Europe

On the primary listing at the NYSE under the ticker JNJ, the shares recently traded near 241 dollars, with the Financial Times data showing a 52-week range between roughly 151 and 252 dollars. The closing price cited for Wednesday stood at 241.00 dollars, around 4.25 percent below the 52-week high of 251.71 dollars set on March 2, 2026, indicating resilient demand in the large-cap healthcare segment. Financial Times market summary for JNJ on NYSE

In Germany, Johnson & Johnson is also quoted on the Munich exchange in euros, where the Financial Times reports a last trade around 211 euros and a 52-week high near 213 euros. This secondary listing allows euro-based investors to gain exposure without direct dollar trading, while the pricing remains tied closely to movements of the NYSE line and the EUR-USD exchange rate. FT data for JNJ in Munich trading

The products behind the healthcare giant

Johnson & Johnson generates its revenue in three main areas: innovative medicines, medical technology and consumer health products such as Tylenol pain relief or Listerine mouthwash. Its pharma division, which includes treatments in oncology and immunology, has been the primary growth driver in recent years and remains a key profit contributor alongside the medtech portfolio.

Where the stock trades today

The Johnson & Johnson shares (US4781601046) traded on 2026-06-25 at 241.10 dollars on the NYSE, based on delayed price data, with this level also used as the reference in the accompanying fact box.

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a qualified advisor before making investment decisions.